Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivimed LabsNSE:VIVIMEDLAB +0.61%31 Intrinsic Value: Projected FCF is ₹57.36 as of Sep. 07, 2026. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 31/100 and a GF Value™ of ₹2.40 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 635 Drug Manufacturers companies, Vivimed Labs ranks better than 99.06% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-07), Vivimed Labs's Intrinsic Value: Projected FCF is ₹57.36. The stock price of Vivimed Labs is ₹6.58. Therefore, Vivimed Labs's Price-to-Intrinsic-Value-Projected-FCF of today is 0.1.
The historical rank and industry rank for Vivimed Labs's Intrinsic Value: Projected FCF or its related term are showing as below:
NSE:VIVIMEDLAB'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.04 Med: 0.09 Max: 0.32
Current: 0.11
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Vivimed Labs was 0.32. The lowest was 0.04. And the median was 0.09.
NSE:VIVIMEDLAB's Price-to-Projected-FCF is ranked better than 99.06% of 635
companies
in the Drug Manufacturers industry
Industry Median: 1.56
vs NSE:VIVIMEDLAB: 0.11
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Vivimed Labs's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
6.58
/
58.14359250992
=
0.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivimed Labs Intrinsic Value: Projected FCF Related Terms
Vivimed Labs Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Vivimed Labs's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VIVIMEDLAB vs ZTS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivimed Labs Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Vivimed Labs's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of ₹57.36 mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a Intrinsic Value: Projected FCF of ₹57.36 as of Sep. 07, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Vivimed Labs and its competitors. According to the industry distribution chart, Vivimed Labs ranks #6 out of 635 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is Vivimed Labs' Intrinsic Value: Projected FCF too high?
Vivimed Labs' current Intrinsic Value: Projected FCF is ₹57.36. Based on the distribution chart, Vivimed Labs ranks #6 out of 635 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vivimed Labs has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Intrinsic Value: Projected FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vivimed Labs ranks #6 out of 635 companies for Intrinsic Value: Projected FCF. This places Vivimed Labs in the top 1% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.56, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Vivimed Labs and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivimed Labs's current Intrinsic Value: Projected FCF is ₹57.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.40, compared to a current price of ₹6.58 — trading 174.2% above its estimated fair value. The current Intrinsic Value: Projected FCF is ₹57.36. Vivimed Labs' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Intrinsic Value: Projected FCF is ₹57.36 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued.
The current stock price of ₹6.58 is trading 174.2% above its estimated GF Value™ of ₹2.40.
GuruFocus considers Vivimed Labs to be Significantly Overvalued.
Key valuation signals for NSE:VIVIMEDLAB:
Intrinsic Value: Projected FCF: ₹57.36
GF Value™: ₹2.40 vs. price of ₹6.58 (174.2% above fair value)
No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
31GF Score
Get the complete analysis for NSE:VIVIMEDLAB
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIVIMEDLAB has been successfully added to your 
